脾氨肽冻干粉治疗肺炎支原体肺炎患儿的效果

Effects of lyophilized powder of spleen aminopeptide in treatment of children with mycoplasma pneumoniae pneumonia

目的:观察脾氨肽冻干粉治疗肺炎支原体肺炎(MPP)患儿的效果。方法:回顾性分析2022年9月至2023年8月该院收治的78例MPP患儿的临床资料,根据治疗方案不同将其分为对照组与研究组各39例。对照组采用阿奇霉素序贯疗法联合氨溴索治疗,研究组在对照组基础上采用脾氨肽口服冻干粉治疗,比较两组临床疗效,临床症状及体征消失时间,治疗前后T细胞亚群指标(CD4^(+)、CD4^(+)/CD8^(+)、CD3^(+))水平、炎性指标[粒细胞集落刺激因子(G-CSF)、可溶性细胞间黏附分子-1(s ICAM-1)、白细胞介素(IL)-12、IL-18]水平,以及不良反应发生率。结果:研究组治疗总有效率为94.87%(37/39),高于对照组的76.92%(30/39),差异有统计学意义(P<0.05);研究组发热、咳嗽、肺部啰音、气喘等临床症状及体征消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)、CD3^(+)水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组G-CSF、s ICAM-1、IL-12、IL-18水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在阿奇霉素序贯疗法联合氨溴索治疗基础上采用脾氨肽冻干粉治疗MPP患儿可提高治疗总有效率和T细胞亚群指标水平,缩短临床症状及体征消失时间,降低炎性指标水平,其效果优于单纯阿奇霉素序贯疗法联合氨溴索治疗。

Objective:To observe effects of lyophilized powder of spleen aminopeptide in treatment of children with mycoplasma pneumoniae pneumonia(MPP).Methods:The clinical data of 78 children with MPP admitted to the hospital from September 2022 to August 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and study group,39 cases in each group.The control group was treated with Azithromycin sequential therapy combined with Ambroxol,while the study group was treated with lyophilized powder of spleen aminopeptide orally on the basis of that of the control group before and after the treatment.The clinical efficacy,the disappearance time of clinical symptoms and signs,the levels of T cell subsets indexes(CD4^(+),CD4^(+)/CD8^(+),CD3^(+))and inflammatory factors[granulocyte colonystimulating factor(G-CSF),soluble intercellular adhesion molecule-1(sICAM-1),interleukin(IL)-12,IL-18].and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 94.87%(37/39),which was higher than 76.92%(30/39)in the control group,and the difference was statistically significant(P<0.05).The disappearance time of clinical symptoms and signs such as fever,cough,pulmonary rales and asthma in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)and CD3^(+)in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of G-CSF,sICAM-1,IL-12 and IL-18 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:On the basis of Azithromycin sequential therapy combined with Ambroxol treatment,spleen aminopeptide in the treatment of the children with MPP can improve the total effective rate of treatment and the T cell subsets levels,shorten the disappearance time of clinical symptoms and signs,and reduce the levels of inflammatory factors.Moreover,it is superior to single Azithromycin sequential therapy combined with Ambroxol treatment.